The first experience of using tenecteplase for the thrombolytic therapy in ischemic stroke in the Russian Federation
- 5 March 2026
- journal article
- abstracts
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (2) , 53-58
Abstract
Thrombolytic therapy (TLT) is an effective treatment for ischemic stroke (IS). Three fibrinolytic agents are currently registered in the Russian Federation for the treatment of IS, including tenecteplase, which has demonstrated high efficacy and safety in several randomized controlled trials. We present three clinical case reports of patients with IS who, for the first time in the Russian Federation, underwent TLT with the domestically produced biosimilar of tenecteplase, Nektelisa. In all three patients with IS, we observed significant regression of neurological deficits after administration of tenecteplase within the first hour after TLT. The dose was adjusted according to the instructions for use, taking into account the patient’s body weight. In all three cases, the same neuroimaging method was used 24 hours after TLT as upon admission. No increase in the ischemic area was observed in any of the patients after 24 hours. In one case, a minor, clinically asymptomatic subarachnoid hemorrhage was detected, accompanied by rapid and complete recanalization of the occluded artery within the first 30 minutes after drug administration. In all three cases, we did not observe any other extracerebral hemorrhagic events. All patients were admitted with significant impairment of neurological functions and were discharged with mild or no significant impairment.Keywords
This publication has 24 references indexed in Scilit:
- Intravenous Tenecteplase before Thrombectomy in StrokeNew England Journal of Medicine, 2025
- Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trialThe Lancet Neurology, 2024
- Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021The Lancet Neurology, 2024
- Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without ThrombectomyNew England Journal of Medicine, 2024
- Efficacy and safety of intravenous tenecteplase compared to alteplase before mechanical thrombectomy in acute ischemic stroke: a meta-analysisJournal of Neurology, 2024
- Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trialThe Lancet, 2024
- Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: a secondary analysis of the AcT randomised clinical trialStroke and Vascular Neurology, 2024
- Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trialThe Lancet, 2023
- Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trialThe Lancet, 2022
- Bridging Therapy or IV Thrombolysis in Minor Stroke with Large Vessel OcclusionAnnals of Neurology, 2020